Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Camzyos (mavacamten) is a prescription drug that works to treat obstructive hypertrophic cardiomyopathy (HCM) by relaxing your heart muscle, allowing it to pump blood more easily. Doctors ...

Boxed safety warning The label for Camzyos does however include a boxed warning for worsening heart failure, which is tied to the mechanism of the drug in reducing LVEF and the workload on the ...

Camzyos only comes as a brand-name drug. It’s not currently available in a generic version. A generic contains an exact copy of the active ingredient in a brand-name medication but tends to cost ...

Camzyos (mavacamten) was approved by the FDA in April to treat obstructive hypertrophic ... The FDA is due to decide on the new label by 16 June next year. "We see a lot of potential to drive ...

Camzyos (mavacamten), a first-in-class heart disease drug, was approved by the FDA on April 28, 2022 to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), a genetic condition that causes ...